Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Cancer Metastatic × Paclitaxel × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 472 Carcinoma, Non-Small-Cell Lung 398 Ovarian Neoplasms 273 Lung Neoplasms 166 Neoplasms 128 Fallopian Tube Neoplasms 122 Esophageal Neoplasms 110 Stomach Neoplasms 107 Neoplasm Metastasis 98 Carcinoma, Ovarian Epithelial 98 Triple Negative Breast Neoplasms 94 Endometrial Neoplasms 79 Squamous Cell Carcinoma of Head and Neck 76 Head and Neck Neoplasms 67 Esophageal Squamous Cell Carcinoma 64 Uterine Cervical Neoplasms 61 Recurrence 43 Parkinson Disease 4, Autosomal Dominant Lewy Body 38 Adenocarcinoma of Lung 38 Urinary Bladder Neoplasms 37 Adenocarcinoma Of Esophagus 33 Melanoma 32 Carcinoma 32 Small Cell Lung Carcinoma 28 Prostatic Neoplasms 28 Pancreatic Neoplasms 27 Carcinoma, Squamous Cell 27 Breast Neoplasms, Male 26 Unspecified Adult Solid Tumor, Protocol Specific 25 Colorectal Neoplasms 24

Interventions

Fulvestrant 5 Letrozole 4 exemestane 3 Capecitabine 3 Anastrozole 3 ribociclib 2 dalpiciclib 2 apatinib 2 Gemcitabine 2 tusamitamab ravtansine 1 trastuzumab deruxtecan 1 pyrotinib 1 patritumab deruxtecan 1 palbociclib 1 olaparib 1 nirogacestat 1 margetuximab 1 irinotecan sucrosofate 1 fluzoparib 1 abemaciclib 1 Zoledronic Acid 1 Vinorelbine 1 Trastuzumab 1 Tamoxifen 1 Paclitaxel 1 Neoadjuvant Therapy 1 Liposomes 1 Irinotecan 1 Ga(III)-DOTATOC 1 Everolimus 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04603183 2025-12-12

ABIGAIL

MedSIR

Phase 2 Completed

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡